Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMC

Fucoxanthin and Its Metabolite Fucoxanthinol Do Not Induce Browning in Human Adipocytes

Rebello CJ., Greenway FL., Johnson WD., Ribnicky D., Poulev A., Stadler K.

Laboratory Study, published in J Agric Food Chem (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Agric Food Chem (2017)
Reported sample size
—
Source database
Europe PMC
PMID
29172481
PMCID
PMC5751931
DOI
10.1021/acs.jafc.7b03931
Citations
17

Abstract (original English)

Rodent studies suggest that the antiobesity effects of fucoxanthin relate to activation of brown fat and conversion of white adipocytes to the brown phenotype. To evaluate the browning effect in human adipocytes, we investigated the genes involved in browning and measured the oxygen consumption rate (OCR). Data were analyzed by one way ANOVA. Relative to control, fucoxanthinol (1 μM, 0.1 μM, 0.01 μM, 1 nM, 0.1 nM), the metabolite present in human plasma, stimulated lipolysis acutely (mean ± SEM: 4.2 ± 0.8, 3.1 ± 0.6, 4.1 ± 0.9, 3.8 ± 0.7, 3.8 ± 0.7, respectively, p 0.05). Thus, in human adipocytes, fucoxanthin and its metabolite do not stimulate conversion of white adipocytes to the brown phenotype.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesHumansbeta CaroteneXanthophyllsPPAR gammaLipolysisGlucose Transporter Type 4Adipose Tissue, BrownUncoupling Protein 1Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.